graft versus host disease


Also found in: Dictionary, Acronyms.

graft ver·sus host dis·ease (GVHD),

an incompatibility reaction (that may be fatal) in a subject (host) of low immunologic competence who has been the recipient of immunologically competent lymphoid tissue from a donor who is immunologically different from the recipient; the reaction, or disease, is the result of action of the transplanted cells against those host tissues that possess an antigen not found in the donor. Seen most commonly following bone marrow transplantation, acute disease is seen after 7-30 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Synonym(s): GVH disease

Graft versus host disease

A life-threatening complication of bone marrow transplants in which the donated marrow causes an immune reaction against the recipient's body.
References in periodicals archive ?
Mottok et al., "Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility," Virchows Archiv, vol.
* The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects
* A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The company plans to conduct the Phase one clinical trial, which is entitled 'An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease', at a number of clinical centres in the UK and Australia.
JR-031 is a treatment for acute graft versus host disease (GVHD), a severe complication arising from hematopoietic cell transplants.
NEW YORK, N.Y., September 29, 2014 -- The graft versus host disease (GVHD) market was valued at $297 million in 2013, and is expected to increase to $409 million in 2018 at a CAGR of 6.61 percent, according to a report published in August.
[ClickPress, Wed May 14 2014] Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2014
SangStat Medical Corporation, Fremont, CA., and Abgenix, Inc., Fremont, CA, announced they are discontinuing a study using the ABX-CBL antibody to treat patients with graft versus host disease (GVHD).
Mesoblast announced that recent meetings held with the United States FDA support its planned regulatory filing for commercialization of remestemcel-L in pediatric patients with steroid refractory acute graft versus host disease. Mesoblast gained agreement from the FDA on the proposed chemistry and manufacturing for commercialization.
No patients treated with Lenti-D had graft versus host disease, and there was no graft rejection or clonal dominance.
The product is used to prevent and decrease the severity and incidence of graft versus host disease in patients eligible for haematological stem cell transplant.